ArticleFuture virology2011
Oncolytic poliovirus against malignant glioma.
Article in Future virology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 53 citations in OpenAlex.
- Engineered bacteria launch and control an oncolytic virus.Nature biomedical engineering · 2026Article
- Review
- Novel Therapies in Glioblastoma Treatment: Review of Glioblastoma; Current Treatment Options; and Novel Oncolytic Viral Therapies.Medical sciences (Basel, Switzerland) · 2023Review
- Recent Developments in Glioblastoma Therapy: Oncolytic Viruses and Emerging Future Strategies.Viruses · 2023Review
- Recombinant Viral Vectors for Therapeutic Programming of Tumour Microenvironment: Advantages and Limitations.Biomedicines · 2022Review
- Therapeutic Implementation of Oncolytic Viruses for Cancer Immunotherapy: Review of Challenges and Current Clinical Trials.Journal of biomedical science and research · 2022Article
- Immunovirotherapy for the Treatment of Glioblastoma and Other Malignant Gliomas.Neurosurgery clinics of North America · 2021Review
- Personalizing Oncolytic Virotherapy for Glioblastoma: In Search of Biomarkers for Response.Cancers · 2021Review
- Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas.Frontiers in immunology · 2021Review
- Oncolytic Virotherapy in Glioma Tumors.International journal of molecular sciences · 2020Review
- Targeting PVR (CD155) and its receptors in anti-tumor therapy.Cellular & molecular immunology · 2019Review
- Molecular mechanism of poliovirus Sabin vaccine strain attenuation.The Journal of biological chemistry · 2018Article
- Poliovirus Receptor (CD155) Expression in Pediatric Brain Tumors Mediates Oncolysis of Medulloblastoma and Pleomorphic Xanthoastrocytoma.Journal of neuropathology and experimental neurology · 2018Article
- Advances in immunotherapeutic research for glioma therapy.Journal of neurology · 2018Review
- Glioblastoma: new therapeutic strategies to address cellular and genomic complexity.Oncotarget · 2018Review
- Oncolytic Virotherapy: A Contest between Apples and Oranges.Molecular therapy : the journal of the American Society of Gene Therapy · 2017Review
- Comment on: Glioblastoma multiforme outcomes of 107 patients treated in two local institutions.Singapore medical journal · 2017Article
- Oncolytic Virotherapy for the Treatment of Malignant Glioma.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2017Review
- Expediting Viral Therapies For Cancers To the Clinic.Molecular therapy : the journal of the American Society of Gene Therapy · 2016Article
- The Practical Consideration of Poliovirus as an Oncolytic Virotherapy.American journal of virology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
In cancerous cells, physiologically tight regulation of protein synthesis is lost, contributing to uncontrolled growth and proliferation. We describe a novel experimental cancer therapy approach based on genetically recombinant poliovirus that targets an intriguing aberration of translation control in malignancy. This strategy is based on the confluence of several factors enabling specific and efficacious cancer cell targeting. Poliovirus naturally targets the vast majority of ectodermal/neuroectodermal cancers expressing its cellular receptor. Evidence from glioblastoma patients suggests that the poliovirus receptor is ectopically upregulated on tumor cells and may be associated with stem cell-like cancer cell populations and proliferating tumor vasculature. We exploit poliovirus' reliance on an unorthodox mechanism of protein synthesis initiation to selectively drive viral translation, propagation and cytotoxicity in glioblastoma. PVSRIPO, a prototype nonpathogenic poliovirus recombinant, is scheduled to enter clinical investigation against glioblastoma.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.